About Michael Katz
Michael Katz is a director of 28bio, Inc. The company works with CNS-3D brain organoids and has shown they can predict seizure risk in small molecule drugs.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Michael Katz in the role, so the role may have started earlier or lasted longer.
28bio, Inc. Current
Director
2020 – Present · Metairie, LA
Brain organoids made from human cells show drug developers how a candidate may affect patients before it reaches the clinic.
Key Colleagues at Startups
The people Michael Katz works with at each company, as listed on that company's latest Form D.
28bio, Inc. · Form D/A, Oct 29, 2026
Alif Saleh
Chief Executive Officer and director
David Weiner
Chief Scientific Officer and director
DP
Dale Pfost
Director
MK
Miklos Kobor
Director
Paul Friel
Director